RAC1 and cancer: It inhibited Rac1 and Cdc42 activity in cells at low‐micromolar concentrations.84 The same screening method identified AZA197 (46), which specifically inhibited Cdc42‐Dbs (RhoGEF) interactions by 61 % in vitro, although no IC50 value was calculated.85 It blocked Cdc42‐dependent migration and altered the cell morphology of cancer cells, whilst also suppressing colon cancer growth in vivo.